Skip to main contentSkip to navigation
Sirius Investors

MESO Stock: Mesoblast Limited Stock Price, Analysis & Insights

Get live MESO stock price $13.93, comprehensive Mesoblast Limited stock analysis, charts, news, and expert forecast. Real-time MESO stock data and investment insights.

13.93
2.45%Today
MESOMesoblast Limited • NASDAQ Global Select • Healthcare
Market Cap
1.79B
Volume
24.69K
52W High
21.50
52W Low
9.88

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The ...

Company Information

CEO
Silviu Itescu
Sector
Healthcare
Industry
Biotechnology
Employees
73

Contact Information

Address
55 Collins Street
Country
AU

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.79) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Mesoblast Limited shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Mesoblast Limited
  • Investors should consider how Mesoblast Limited fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

1.79B

P/E Ratio (TTM)

-21.43

Beta

0.79

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.